Hovione Capital

Hovione Capital, now known as Bionova Capital, is a healthcare-focused venture capital firm based in Lisbon, Portugal. The firm was established in 2015 by the shareholders of Hovione, a leading pharmaceutical company. In February 2021, Hovione Capital rebranded to Bionova Capital to reflect its expanded focus on disruptive life science companies across Europe. Bionova Capital invests in early-stage companies specializing in breakthrough therapeutics, medtech, and digital health. The firm has built a strong reputation for being an active, value-adding investor, supporting startups with capital, strategic guidance, and access to a broad network of industry experts. The firm’s portfolio includes successful investments like CellmAbs, a notable biotech deal in Europe. Recently, Bionova Capital has shifted its new investment activities to Biovance Capital Partners, an independent venture capital company established by the Bionova team. This new fund, Biovance Capital Fund I, focuses on early-stage biotech companies and has secured up to €60 million for its investment activities.